[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-radiotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644622","phase-2-phase-ii-trial-of-sfrt-plus-chemo-immunotherapy-for-la-nsclc-with-suboptimal-neoadjuvant-response-100644622",false,"NCT07670715","Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response","Spatially Fractionated Radiotherapy Combined With Chemo-immunotherapy for Locally Advanced Non-Small Cell Lung Cancer With Suboptimal Response to Initial Neoadjuvant Therapy: A Single-Arm, Open-Label, Phase II Study","Inclusion Criteria:\n\n1. Histologically confirmed unresectable stage III locally advanced non-small cell lung cancer (LA-NSCLC).\n2. Received at least 2 cycles of standard neoadjuvant chemoimmunotherapy, with suboptimal tumor response verified by post-induction radiological evaluation.\n3. Age ≥ 18 years old.\n4. ECOG performance status of 0 or 1.\n5. Adequate hematologic, hepatic and renal function to complete radiotherapy and consolidation systemic therapy.\n6. Voluntarily sign written informed consent and be capable of following study-related procedures.\n\nExclusion Criteria:\n\n1. Prior thoracic radiotherapy history.\n2. Active uncontrolled autoimmune disorders or persistent severe immune-related adverse events.\n3. Untreated symptomatic brain metastases.\n4. Severe irreversible cardiac, pulmonary, liver or renal dysfunction that cannot tolerate combined radiotherapy and immunotherapy.\n5. Pregnant or breastfeeding women.\n6. Concurrent or previous other malignant tumors within 5 years, except cured basal cell skin cancer and cervical carcinoma in situ.\n7. Any absolute contraindication to lattice radiation therapy or immune checkpoint inhibitor.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Lattice radiation therapy (LRT) is a spatially fractionated thoracic radiotherapy technique that creates alternating high- and low-dose regions within primary lung tumors and metastatic lymph nodes to strengthen local tumor suppression and reduce radiation injury to normal thoracic organs. This study aims to evaluate the efficacy and safety of combining LRT with consolidation chemoimmunotherapy in unresectable stage III LA-NSCLC patients who show suboptimal tumor response to prior neoadjuvant chemoimmunotherapy, through a single-arm Phase II clinical trial. Patients will receive thoracic LRT delivered by a medical linear accelerator. High-dose spherical sub-targets will be contoured within the gross tumor volume of primary lung lesions and regional nodal metastases under standardized dose constraints to spare the lung, heart and esophagus. All enrolled subjects will receive sequential consolidation chemoimmunotherapy administered within one week after finishing LRT. Tumor response, treatment-related adverse events, local tumor control and long-term survival outcomes will be prospectively tracked throughout treatment and long-term follow-up.",[26,27,28,29],"Locally Advanced Non-small Cell Lung Cancer (NSCLC)","Thoracic Radiotherapy","Immune Checkpoint Inhibitors","Neoadjuvant Chemoimmunotherapy",[31,32,29],"spatially fractionated radiotherapy","Locally Advanced NSCLC","NOT_YET_RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":20},"2026-07-01",{"date":41,"type":20},"2028-07-01",{"name":43,"class":44},"Tianjin Medical University Cancer Institute and Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100595840","phase-2-radiotherapy-plus-anlotinib-in-la-nsclc-intolerable-to-ccrt-100595840","NCT07037680","Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT","Efficiency and Safety of Radiotherapy Combined With Anlotinib in Locally Advanced Non-small Cell Lung Cancer Patients Intolerable to Concurrent Chemoradiotherapy: A Phase II Single-arm Trial","Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK\u002FROS1-mutated locally advanced unresectable NSCLC were screened.\n\nInclusion Criteria:\n\n1. ≥18 years old with no restrictions on sex;\n2. Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;\n3. Eastern cooperative oncology group (ECOG) score ≤2 was required;\n4. Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;\n5. .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;\n6. No symptoms of hemoptysis;\n7. Adequate hepatic and renal functions with a negative urine protein;\n8. Expected survival of more than 6 months.\n\nExclusion Criteria:\n\n1. currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ;\n2. previous malignancy within five years;\n3. thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months;\n4. uncontrolled or active pulmonary inflammation;\n5. participated in other clinical trials;\n6. Pregnant women.",{"count":54,"type":20},44,[23],"Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.",[58,27,59],"Locally Advanced Non-Small Cell Lung Cancer","Safety",[61,62,63,64,65],"thoracic radiotherapy","non-small cell lung carcinoma","locally advanced","safety","Anlotinib","RECRUITING","2025-07-03",{"date":69,"type":37},"2025-07-09",{"date":71,"type":37},"2024-01-01",{"date":73,"type":20},"2026-06-30",{"name":75,"class":44},"JIANYANG WANG",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100585040","optimizing-radiation-dose-and-utilizing-wearable-devices-to-reduce-arrhythmia-risk-in-patients-undergoing-thoracic-radiotherapy-a-prospective-cohort-study-100585040","NCT06897189","Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with solid tumors requiring thoracic radiotherapy\n* Undergoing curative-intent radiotherapy\n* Expected survival \\> 4 months\n* Adults aged ≥ 20 years\n* ECOG performance status 0-2\n* Classified as moderate-to-high risk for radiation-induced cardiotoxicity per the 2022 ESC guidelines\n* Able to read, understand, and sign the informed consent form\n\nExclusion Criteria:\n\n* History of prior thoracic radiotherapy\n* Inability to provide informed consent or refusal to participate\n* Pre-existing arrhythmia diagnosed through medical history or pre-treatment evaluation\n* Expected survival ≤ 4 months\n* Classified as low risk for radiation-induced cardiotoxicity per the 2022 ESC guidelines\n* Unsuitability for Wearable CR device use","20 Years",{"count":84,"type":20},111,"OBSERVATIONAL","This prospective observational cohort study aims to assess the risk of radiation-induced cardiotoxicity in patients undergoing thoracic radiotherapy by integrating real-time arrhythmia monitoring using wearable cardiac rehabilitation (wearable CR) devices and AI-based cardiac substructure segmentation. The study will analyze radiation dose exposure to key cardiac structures, including the sinoatrial node (SAN) and pulmonary veins (PV), to identify risk factors for atrial fibrillation (AF) and other arrhythmias. Patients will receive wearable CR monitoring at 3, 12, and 24 months post-radiotherapy, with cardiology follow-up and intervention based on standard clinical guidelines. The study will recruit 111 patients over three years, with a two-year follow-up after radiotherapy. The primary endpoint is the incidence of grade 3+ AF within 2 years, with secondary outcomes including any-grade arrhythmia rates, arrhythmia burden, and survival analysis. By establishing a prospective thoracic radiotherapy patient cohort, this study aims to identify dose-related risk factors, improve early detection and management of radiation-induced arrhythmias, and provide evidence-based strategies to enhance treatment safety and efficacy.",[88,27,89,90,91],"Cardiotoxicity","Wearable Electronic Devices","Thoracic Neoplasms","Atrial Fibrillation","2025-04-16",{"date":94,"type":37},"2025-04-18",{"date":96,"type":20},"2025-05",{"date":98,"type":20},"2030-02-16",{"name":100,"class":44},"Yonsei University"]